新型双表位ELISA揭示循环脂蛋白脂肪酶的异质性:区分完整LPL与总LPL
研究开发了F1A/R23B双表位ELISA,可同时识别LPL的N端和C端表位,操作上定义为「完整LPL」。该法检测限0.01 ng/mL,批内和批间变异系数均低于7%。在健康志愿者、多因素乳糜微粒血症综合征患者及GPIHBP1自身抗体综合征患者中,完整LPL仅占总LPL免疫反应性的少数,且在特定临床条件下呈现差异。
要点
- 双表位ELISA可区分保留N端和C端表位的完整LPL与总LPL免疫反应性。
- 完整LPL仅占总LPL免疫反应性的少数,血浆中存在30-35 kDa的N端反应性异质性片段。
- GPIHBP1自身抗体综合征患者完整LPL浓度及完整/总LPL比值显著降低。
核心结论
- F1A/R23B ELISA可区分保留两个抗体定义末端区域的LPL种类与传统总LPL免疫反应性。
- 循环LPL在特定实验和临床条件下存在生化异质性。
- 完整LPL测定的增量临床价值尚需前瞻性研究确立。
研究设计与样本
- 研究采用重组全长LPL、分析验证、免疫印迹、互惠免疫沉淀-免疫印迹、肝素后动力学、LPL活性测定及离体tetrahydrolipstatin处理评价F1A/R23B ELISA。
- 临床分析纳入健康志愿者19例、多因素乳糜微粒血症综合征患者170例及GPIHBP1自身抗体综合征患者17例。
主要发现
- 该法检测限为0.01 ng/mL,稀释线性良好,批内和批间变异系数均低于7%。
- 约55-kDa血浆种类可被两个末端区域识别,而30-35-kDa N端反应性种类显示分子异质性。
- 完整LPL仅占总LPL免疫反应性的少数,在两名个体中肝素给药后与LPL活性大致平行。
- 健康参与者中完整LPL及完整/总LPL比值显著降低。
- MCS中胰腺炎病史与较高的TG/完整LPL比值相关,但完整LPL单独无显著差异;GPIHBP1自身抗体综合征患者完整LPL浓度及完整/总LPL比值显著降低。
临床怎么用
- 该双表位ELISA可用于区分循环中保留N端和C端表位的完整LPL与传统总LPL免疫反应性。
- 完整LPL及其与总LPL比值在GPIHBP1自身抗体综合征中显著降低,可能有助于该病的生化识别。
局限性
- 完整LPL测定的增量临床价值尚需前瞻性研究确立。
- 循环LPL的生化异质性结论仅限于本研究特定的实验和临床条件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Conventional immunoassays measure total circulating lipoprotein lipase (LPL) but do not distinguish molecular species retaining both terminal regions. We developed a dual-epitope E LISA that measures LPL simultaneously recognized through defined N- and C-terminal epitopes, operationally termed "intact LPL." METHODS: The F1A/R23B ELISA was evaluated using recombinant full-length LPL, analytical validation, immunoblotting, reciprocal immunoprecipitation-immunoblotting, post-heparin kinetics, LPL activity measurements, and ex vivo tetrahydrolipstatin treatment. Clinical analyses included healthy volunteers (n = 19), patients with multifactorial chylomicronemia syndrome (MCS; n = 170), and patients with GPIHBP1 autoantibody syndrome (n = 17). RESULTS: The assay showed a detection limit of 0.01 ng/mL, good dilutional linearity, and intra- and inter-assay coefficients of variation below 7%. An approximately 55-kDa plasma species was recognized through both terminal regions, whereas 30-35-kDa N-terminal-reactive species demonstrated molecular heterogeneity. Intact LPL represented a minority of total LPL immunoreactivity and broadly paralleled LPL activity after heparin administration in two individuals. In healthy participants, intact LPL and the intact-to-total LPL ratio decreased significantly. In MCS, pancreatitis history was associated with higher triglyceride (TG)/intact LPL ratios, although intact LPL alone did not differ significantly. Patients with GPIHBP1 autoantibody syndrome had markedly reduced intact LPL concentrations and intact-to-total LPL ratios. CONCLUSIONS: The F1A/R23B ELISA distinguishes an LPL species retaining both antibody-defined terminal regions from conventional total LPL immunoreactivity. These findings demonstrate biochemical heterogeneity of circulating LPL under the specific experimental and clinical conditions examined in this study. Prospective studies are required to establish the incremental clinical value of intact LPL measurement.
引用
- Nagasawa T, Nakajima K, Shirakawa T, et al. A novel dual-epitope ELISA reveals heterogeneity of circulating lipoprotein lipase: distinguishing intact LPL from total LPL. Clin Chim Acta. 2026. PMID: 42893715. doi:10.1016/j.cca.2026.122896
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。